文献速递冠心病

高电压聚焦脉冲场消融治疗瘢痕相关室性心动过速:首例人体VCAS试验

High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.
PubMed 文献 · Circulation · 2025-10-10

VCAS是一项首例人体研究,评估新型高电压聚焦脉冲场消融(PFA)导管治疗瘢痕相关室性心动过速(VT)的安全性和有效性。26例患者接受消融,急性成功率92%,术后VT/VF负荷较基线降低98%,无VT/VF或ICD放电生存率81.8%(95%CI 67.1-99.8),180天内主要安全终点事件发生率11.5%。

要点

  • 高电压PFA导管可有效实现瘢痕相关VT的透壁消融。
  • 术后VT/VF负荷较基线显著降低98%。
  • 180天内主要安全终点事件发生率为11.5%。

核心结论

  • 高电压PFA导管能高效递送透壁心室 lesion 以治疗瘢痕相关VT。

研究设计与样本

  • VCAS为首次人体研究,在2个中心纳入26例瘢痕相关VT患者,使用8.5F压力感知PFA导管,脉冲场lesion由5次应用组成,每次<200 ms,高电压(>10 kV)单相波形并QRS同步,随访6个月。

主要发现

  • 急性手术成功24/26(92%),每例患者需21(IQR 14-24)个lesion,消融时间31分钟(IQR 19-42)。
  • 临床VT诱发在消融前14/16(88%)患者中成功,消融后仅1/16(6%,P<0.001)。
  • 10例患者接受高密度心内膜-心外膜电压标测,其中9例仅行心内膜PFA者均观察到透壁组织均质化(100%)。
  • 无复发性VT/VF或ICD放电生存率为81.8%(95%CI 67.1-99.8)。
  • 消融后VT/VF发生率较基线降低98%(中位数[IQR] 6[1-11] vs 0[0-0],P<0.001)。

关键数值与推荐

  • 急性手术成功定义为24/26(92%)患者达成。
  • 临床VT诱发消融前14/16(88%) vs 消融后1/16(6%),P<0.001。
  • 透壁组织均质化在9/9(100%)仅行心内膜PFA的患者中观察到。
  • 无VT/VF或ICD放电生存率81.8%(95%CI 67.1-99.8)。
  • 180天内主要安全终点事件3/26(11.5%):心源性休克、心力衰竭住院、腹膜后出血。

临床怎么用

  • 高电压PFA导管可用于瘢痕相关VT的消融治疗,实现高急性成功率和显著降低VT/VF负荷。
  • 需关注围术期主要安全事件,包括心源性休克、心衰住院和出血。

局限性

  • 首次人体研究,样本量小(26例),女性比例低(4%),随访6个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unlike the tremendous progress made in atrial fibrillation ablation, the greatest unmet clinical need is for innovative ablation treatments for scar-related ventricular tachycardia (VT), particularly given the thick, often fibrotic tissue characteristic of the scarred substrate. A focal pulsed field ablation (PFA) catheter with a novel waveform was designed: high voltage to provide tissue penetration and low energy (using short-duration pulses) to avoid tissue overheating. We present the outcomes of VCAS (Ventricular Catheter Ablation Study), a first-in-human study of this PFA catheter to ablate scar-related VT. METHODS: An investigational 8.5F force-sensing PFA catheter was used for scar-VT ablation in ischemic or nonischemic substrates. Pulsed field lesions consisted of 5 applications, each <200 ms, of a high-voltage (>10 kV) monophasic waveform with QRS synchronization. The PFA catheter was localized by electrical impedance-based navigation. A subcohort of patients without previous cardiac surgery underwent epicardial ventricular mapping at baseline and after endocardial PFA to assess for transmurality of endocardial pulsed field lesions. Study end points included procedural efficiency, safety, and effectiveness to final follow-up of 6 months. RESULTS: At 2 centers, 26 patients underwent ablation: 66±9 years of age, 4% women, left ventricular ejection fraction 32±10%, VT storm 42%, previous VT ablation 42%. Acute procedural success, achieved in 24 (92%) patients, required 21 (interquartile range, 14-24) lesions per patient with a transpired ablation time of 31 minutes (19-42). Clinical VT was induced in 14 of 16 patients (88%) before ablation and 1 of 16 patients (6%, P<0.001) after ablation. High-density epi-endo voltage mapping was performed in 10 patients [42%]; of the 9 patients undergoing endocardial-only PFA, transmural tissue homogenization was observed in all 9 (100%) patients. Freedom from recurrent VT/ventricular fibrillation (VT/VF) or implantable cardioverter defibrillator shock was 81.8% (95% CI, 67.1-99.8). Regarding VT/VF burden, the incidence rate of postablation VT/VF significantly decreased from baseline to after PFA by 98% (median [IQR], 6 [1-11] versus 0 [0-0], respectively; P<0.001). Primary safety end points within 180 days occurred in 3 of 26 (11.5%) patients: cardiogenic shock, heart failure hospitalization, and retroperitoneal bleed. CONCLUSIONS: In this first-in-human study, the high-voltage PFA catheter efficiently delivered transmural ventricular lesions to treat scar-related VT. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06203262.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Reddy, Koruth, Peichl, et al. High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial. Circulation. 2025. PMID: 41071961. doi:10.1161/CIRCULATIONAHA.125.077025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。